百晓学者学者目录

刘丹

副教授、博士生导师、教授、研究员、硕士生导师、讲师，徐州医科大学

精选作品

期刊论文

2026

ESM1 SUMOylation mediates bevacizumab resistance in ovarian cancer through ITGB1-FAK-driven angiogenesis.

Xiao-min Ran, Juan Zhang, Juan Yang, Hui Li, Dan Liu, Xing Tang, Wen-chao Zhou, Xueru Liu, Yu-Kun Li, Bikang Yang

Cell Reports

DOI

2026

ESM1 drives cisplatin resistance and ferroptosis resistance via ERBB2/FAK/SRC/HSPB1/NF-κB signaling in ovarian cancer

Juan Zhang, Yingzheng Tan, Hai-Bing Yang, Xing Tang, Dan Liu, Wen-chao Zhou, Tian Zeng, Xueru Liu, Miao Li, Xun Chen, Juan Zou, Yu-Kun Li

iScience

DOI

2026

靶向Siglec-6 CAR-T细胞的体外优化及其抗急性髓系白血病的临床前评价

胡延梦子，李紫涵，管章春，刘丹，施明

《中国肿瘤生物治疗杂志》

2026

靶向FAP的CAR-T细胞通过重塑肿瘤微环境抑制乳腺癌生长的临床前研究

王海镕，曲格希，孙齐仟钰，刘丹，李思瑾，施明

《中国肿瘤生物治疗杂志》

2025

Decoding tumor angiogenesis: pathways, mechanisms, and future directions in anti-cancer strategies

Xueru Liu, Juan Zhang, Ting Yi, Hui Li, Xing Tang, Dan Liu, Dai-Chao Wu, Yu-Kun Li

Biomarker Research

DOI

2025

国产与进口CD3/CD28激活磁珠制备CAR-T细胞的性能对比

魏献政，张书瑜，金钰航，王璞，王旭，郑骏年，刘丹，施明

《中国肿瘤生物治疗杂志》

2024

Development and Validation of a Computed Tomography-Based Model for Noninvasive Prediction of the T Stage in Gastric Cancer: Multicenter Retrospective Study

Jin Tao, Dan Liu, Fu-Bi Hu, Xiao Zhang, Hongkun Yin, Huiling Zhang, Kai Zhang, Zixing Huang, Kun Yang

Journal Of Medical Internet Research，Vol. 26

DOI

2024

The role of ESM1 in the lipids metabolic reprogramming and angiogenesis of lung adenocarcinoma cells

Wenchang Feng, Yi-Lee Ting, Xing Tang, Dan Liu, Wen-chao Zhou, Yu-Kun Li, Zhenyu Shen

Heliyon

DOI

2024

ANGPTL4 accelerates ovarian serous cystadenocarcinoma carcinogenesis and angiogenesis in the tumor microenvironment by activating the JAK2/STAT3 pathway and interacting with ESM1

Yu-Kun Li, An-bo Gao, Tian Zeng, Dan Liu, Qun-feng Zhang, Xiao-min Ran, Zhen-zi Tang, Yan Li, Jue Liu, Ting Zhang, Gang-qing Shi, Wen-chao Zhou, Wen-da Zou, Juan Peng, Juan Zhang, Hui Li, Juan Zou

Journal of Translational Medicine

DOI

2024

Lactate drives the ESM1-SCD1 axis to inhibit the antitumor CD8+ T-cell response by activating the Wnt/β-catenin pathway in ovarian cancer cells and inducing cisplatin resistance.

Zhi-Wen Fan, Mingzhu Ye, Dan Liu, Wen-chao Zhou, Tian Zeng, Sili He, Yu-Kun Li

International Immunopharmacology

DOI

2024

Identification of a Novel Prognostic Lymphangiogenesis-Related Signature Associated with Tumor Immunity for Guiding Therapy in Lung Adenocarcinoma

Juan Peng, Dan Liu, Hong-feng Zhang, Qi-Hao Hu, Wen Chen, Juan Zou, Juan Zhang, Hui Li, An-bo Gao, Yu-Kun Li

Analytical Cellular Pathology

DOI

2024

Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial

Ya-Kun Wang, J. Gong, Airong Wang, Jia Wei, Zhi Peng, Xi-Cheng Wang, Jun Zhou, Chang-Song Qi, Dan Liu, Jian Li, Ming Lu, Zhi-Hao Lu, Yan-Shuo Cao, Jia-Jia Yuan, Ruyan Zhang, Jian-Min Fang, Xiao-Tian Zhang, Lin Shen

EClinicalMedicine

DOI

2024

BCMA-CD19 bispecific CAR-T therapy in refractory chronic inflammatory demyelinating polyneuropathy

Wei Zhang, Dan Liu, Tao Zhang, Jiang Cao, Gang Wang, Huizhong Li, Su Zhou, Ruixue Zhang, Yuqiao Wang, Jinyu Li, Zixuan Zhang, Hao Chen, Yong Zhang, Shenyang Zhang, Jie Zu, Xiaopeng Wang, Chuanying Xu, Manli Zhou, Ming Shi, Guiyun Cui, Junnian Zheng

hLife

2024

基于BCMA突变体构建BCMA CAR-T细胞体外杀伤功能评价模型

张小雪，华静涵，侯睿，刘丹，施明，曹江

《中国肿瘤生物治疗杂志》

2023

Comprehensive Analyses and Experiments Confirmed IGFBP5 as a Prognostic Predictor Based on an Aging-genomic Landscape Analysis of Ovarian Cancer.

Tingyu Fan, Li-Li Xu, Hong-feng Zhang, Juan Peng, Dan Liu, Wen-da Zou, Wenchang Feng, M. Qin, Juan Zhang, Hui Li, Yu-Kun Li

Current Cancer Drug Targets

DOI

2023

Pyrotinib alone or in combination with docetaxel in refractory HER2‐positive gastric cancer: A dose‐escalation phase I study

Dan Liu, Fu-Rong Kou, J. Gong, Zhi-Qiang Wang, Xiao-Tian Zhang, Jian Li, Yan Li, Jie Li, Jun Zhou, Ming Lu, Xi-Cheng Wang, Zhi-Hao Lu, Yan-Shuo Cao, J. Zou, Xiaoyu Zhu, Rui-Hua Xu, Lin Shen

Cancer Medicine

DOI

2023

Preliminary safety, efficacy, and pharmacokinetics (PK) results of the EP4 antagonist INV-1120 from a phase I study in Chinese patients with advanced solid tumors.

Chang Liu, Miao Zhang, Jia-Jia Yuan, Dan Liu, J. Gong, Yi Zhu, Lishan Lin, Yong-jun Sun, J. Nippgen, Lin Shen

Journal of Clinical Oncology

DOI

2023

Osemitamab in combination with capecitabine and oxaliplatin (CAPOX) as a first line treatment of advanced G/GEJ cancer: Updated data of cohort C from a phase I/IIa, multi-center study (TranStar102/TST001-1002).

Lin Shen, Dan Liu, Ning Li, Wei-Jian Guo, Tian-Shu Liu, Hong-Li Li, Jiayi Li, Yuxian Bai, Yan-Hong Deng, Z. Zhuang, Mei-Li Sun, Q. Fan, Fuyou Zhao, Liang Han, Z. Xia, Jianming Wang, C.H. Qi, Li Xu, Xueming Qian, C. Germa

Journal of Clinical Oncology

DOI

2022

Safety, tolerability, and preliminary efficacy results in patients with advanced gastric/gastroesophageal junction adenocarcinoma from a phase Ib/II study of CLDN18.2 CAR T-cell therapy (CT041).

Chang-Song Qi, Chang Liu, J. Gong, Jian Li, Dan Liu, S. Ge, Miao Zhang, Zhi Peng, Jun Zhou, Xiao-Tian Zhang, Ji Zheng, Jun Xiao, Daijing Yuan, Yue-ying Peng, Hua-Mao Wang, Zong-Hai Li, Lin Shen

Journal of Clinical Oncology

DOI

2022

A Phase Ib Study of the Simmitecan Single Agent and in Combination With 5-Fluorouracil/Leucovorin or Thalidomide in Patients With Advanced Solid Tumor

Qi Zhang, T. Deng, Fen Yang, Wei-Jian Guo, Dan Liu, Jia-Jia Yuan, Chang-Song Qi, Yan-Shuo Cao, Qiu-Qiong Yu, Huiming Cai, Zhi Peng, Xi-Cheng Wang, Jun Zhou, Ming Lu, J. Gong, Jian Li, Y. Ba, Lin Shen

Frontiers in Pharmacology

DOI

2022

Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results

Chang-Song Qi, J. Gong, Jian Li, Dan Liu, Yan-Ru Qin, S. Ge, Miao Zhang, Zhi Peng, Jun Zhou, Yan-Shuo Cao, Xiao-Tian Zhang, Zhi-Hao Lu, Ming Lu, Jia-Jia Yuan, Zheng-Hang Wang, Ya-Kun Wang, Xiaohui Peng, Hui-Ping Gao, Zhen Liu, Hua-Mao Wang, Daijing Yuan, Jun Xiao, Hong-Jie Ma, Wei Wang, Zong-Hai Li, Lin Shen

Nature Medicine

DOI

2022

Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial

Dan Liu, Jun Zhou, Yongsheng Wang, Ming-Jun Li, Haiping Jiang, Yun-Peng Liu, X. Yin, Minghua Ge, Xiao-Jun Xiang, J. Ying, Jian Huang, Yan-Qiao Zhang, Ying Cheng, Zhigang Huang, Xiang-Lin Yuan, W. Han, D. Yan, Xin-Shuai Wang, Pan Liu, Lin-Na Wang, Xiao-Jing Zhang, Su-Xia Luo, Tianshu Liu, Lin Shen

BMC Medicine

DOI

2022

Genomic characterization of Chinese locally advanced or metastatic gastric cancer.

Xiao-Tian Zhang, Ya-Kun Wang, Xin-Ying Shi, Chang-Song Qi, Zhi Peng, T. Xie, Dan Liu, Siyuan Cheng, Pan-Pan Zhang, Yiqun Zhang, Qian Wan, N. Hu, Zhi-Hua Pei, Dongliang Wang, Lin Shen

Journal of Clinical Oncology

DOI

2022

Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR/BRAF inhibitors

T. Xu, Xi-Cheng Wang, Zheng-Hang Wang, T. Deng, Chang-Song Qi, Dan Liu, Yan-Yan Li, C. Ji, Jian Li, Lin Shen

Therapeutic Advances in Medical Oncology

DOI

2022

Trastuzumab combined with irinotecan in patients with HER2-positive metastatic colorectal cancer: A phase II multicenter single-arm study and exploratory biomarker analysis.

T. Xu, Xi-Cheng Wang, Ying Xin, Zheng-Hang Wang, Ya-Kun Wang, Chang-Song Qi, Dan Liu, Yan-Yan Li, J. Gong, Jian Li, Depei Huang, Lin Shen

Journal of Clinical Oncology

DOI

2022

基于HLA-E功能特点的肿瘤免疫治疗新策略

曹朔文，刘丹，施明

《中国肿瘤生物治疗杂志》

2021

Dysregulated KRAS gene-signaling axis and abnormal chromatin remodeling drive therapeutic resistance in heterogeneous-sized circulating tumor cells in gastric cancer patients.

Yang Chen, Yan-Yan Li, Chang-Song Qi, Cheng Zhang, Dan Liu, You-Ping Deng, Yuanyuan Fu, V. Khadka, D. Wang, S. Tan, Shu-Jun Liu, Zhi Peng, J. Gong, P. Lin, Xiao-Tian Zhang, Jian Li, Yi-Lin Li, Lin Shen

Cancer Letters

DOI

2021

Phase I study of the recombinant humanized anti-HER2 monoclonal antibody–MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors

Yingying Xu, Ya-Kun Wang, J. Gong, Xiao-Tian Zhang, Zhi Peng, X. Sheng, C. Mao, Q. Fan, Yuxian Bai, Y. Ba, D. Jiang, Fen Yang, Chang-Song Qi, Jian Li, Xi-Cheng Wang, Jun Zhou, Ming Lu, Yan-Shuo Cao, Jia-Jia Yuan, Dan Liu, Zheng-Hang Wang, Jian-Min Fang, Lin Shen

Gastric Cancer

DOI

2021

Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphoma.

Dan Liu, Chun-Guang Ma, P. Lu, J. Gong, D. Ye, Siyang Wang, Pei-Jian Peng, Yuxian Bai, Yu-Qin Song, Jian-Hua Chen, O. Jiang, Guojun Zhang, Y. Ba, Li Chen, Jian-Ji Pan, Qi Li, Li-Ling Zhang, S. Gu, X. Yin, B. Cao, W. Han, Haiying Dong, Jian-Ming Guo, Hui-Lai Zhang, Hang Su, Yong-Sheng Jiang, W. Ouyang, Lu-Lin Ma, Yan Sun, Feng Zhang, Jun-Li Lv, Ya-Bing Guo, Chongyuan Xu, J. Qi, Li Wang, Xiang Wang, Zhen Liu, Lin Shen

European Journal of Cancer

DOI

2021

Phase 1 study of SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with advanced solid tumors.

Dan Liu, J. Gong, Tian-Shu Liu, Kun-Yan Li, X. Yin, Yun-Peng Liu, Yong-Sheng Wang, Lin-Na Wang, WEN-LAN L. Wang, Yanyan Zhang, Lin Shen

DOI

2021

Pharmacokinetic study of lenvatinib in Chinese patients with solid tumors.

Dan Liu, Lei Liu, Lin Shen, T. Kubota, Takuya Suzuki, H. Ikezawa, S. Shiba, Yuxian Bai

Future Oncology

DOI

2021

Pyrotinib combined with SHR6390 in the treatment of refractory advanced HER2 positive gastric cancer or solid tumors: Safety and efficacy results from a phase Id trial.

Dan Liu, J. Gong, Yingying Xu, F.-E. Yang, Huajun Li, Lin Shen

Journal of Clinical Oncology

DOI

2020

810 Preliminary safety, tolerability and efficacy results of KN026 in combination with KN046 in patients with HER2 aberrated solid tumors

J. Gong, Lin Shen, Zhi-Gang Dong, Dan Liu, June Xu, Jing Yang, Yue Yang, Y. Qi, J. Men, P. Kong, T. Xu

Journal for ImmunoTherapy of Cancer

DOI

2020

339 Preliminary safety, tolerability and efficacy results of KN026 (a HER2-targeted Bispecific Antibody) in combination with KN046 (an anti-PD-L1/CTLA-4 Bispecific Antibody) in patients (pts) with HER2 aberrated solid tumors

J. Gong, Zhi-Gang Dong, Dan Liu, June Xu, Jing Yang, Yue Yang, Y. Qi, J. Men, P. Kong, T. Xu, Lin Shen

Journal for ImmunoTherapy of Cancer

DOI

2020

URELUMAB (ANTI-CD137 AGONIST) IN COMBINATION WITH VACCINE AND NIVOLUMAB TREATMENTS IS SAFE AND ASSOCIATED WITH PATHOLOGIC RESPONSE AS NEOADJUVANT AND ADJUVANT THERAPY FOR RESECTABLE PANCREATIC CANCER

J. Gong, Lin Shen, Zhi-Gang Dong, Dan Liu

2020

Abstract 5386: In situ detection of CLDN18.2 RNA in circulating tumor cells in gastrointestinal cancer

Xiao-Yi Chong, Linyang Fan, Chang-Song Qi, J. Gong, Zhi Peng, Dan Liu, Yang Chen, Chen-Hui Xu, Yan-Yan Li, C. Ji, Qin Li, Zhi-Yuan Hu, Xiao-Tian Zhang, Lin Shen

Clinical Trials

DOI

2020

Germline Profiling and Molecular Characterization of Early Onset Metastatic Colorectal Cancer

Ting-Jing Xu, Yin-Jie Zhang, Jing Zhang, Chang-Song Qi, Dan Liu, Zheng-Hang Wang, Yan-Yan Li, C. Ji, Jian Li, Xuan Lin, T. Hou, Hao Liu, Lu Zhang, Han-Zhang Han, Lin Shen, Xi-Cheng Wang

Frontiers in Oncology

DOI

2020

Potential Drug-Drug Interactions with Combination Volasertib + Itraconazole: A Phase I, Fixed-Sequence Study in Patients with Solid Tumors.

I. Láng, Dan Liu, H. Fritsch, T. Taube, Evgenii Chizhikov, Bela Liptai

Clinical Therapeutics

DOI

2020

A multicenter, open-label, phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of JMT-101 in patients (pts) with advanced colorectal cancer (ACC).

Jian Li, Lin Shen, J. Gong, Zhi Peng, Dan Liu, Chang-Song Qi, Jia-Jia Yuan, Rong Hu, Xiugao Yang, Tao Li, D. Fu, Rui-Rui Yang, Li Feng, Peng Zhang, Xin Chen, Jing Yuan, Yuan-Yuan Liu, Zhufeng Wu, Yen Cao, Shulin Zhong

Journal of Clinical Oncology

DOI

2020

IMMUNE CHECKPOINT INHIBITOR INDUCED MYOCARDITIS MIMICKING MYOCARDIAL INFARCTION

Jing-Ling Gu, Yuxiao Li, Lan Gao, Peng-Kang He, Dan Liu, Chang-Song Qi, J. Gong, Xi Cao, Wei Ma, He Wang, Song-Yun Chu, Yue-Yuan Li, Wen-Hui Ding, Lin Shen, Jianping Li

Journal of the American College of Cardiology

DOI

2020

Abstract 5381: Elevated PD-L1 and HER2 expression on aneuploid carcinoma cells in malignant ascites accelerate stumor cell immune evasion in gastrointestinal cancer patients

Yang Chen, Chang-Song Qi, Jia-Jia Yuan, Dan Liu, Zhi Peng, Xiao-Tian Zhang, Jian Li, P. Lin, Yi-Lin Li, Lin Shen

Clinical Trials

DOI

2020

一种无标记且实时检测CD19 CAR-T细胞杀伤功能的方法

徐溪悦，刘庶慈，汤安群，马文，郑骏年，刘丹，施明

《医学研究与战创伤救治》

DOI

2020

IL-1β与肿瘤恶性演进关系的研究进展

徐溪悦，刘丹，施明

《中国免疫学杂志》

2019

Abstract 1389: Single-cell sequencing to identify genetic variant accelerating shedding of CTCs into peripheral blood in gastric cancer patients

Yi-Lin Li, Xiao-Tian Zhang, J. Gong, D. Wang, Mingxia Qi, Yan-Yan Li, Dan Liu, Chunxiang Wang, P. Lin, Lin Shen

Clinical research

DOI

2019

基于CRISPR/Cas9技术构建多重sgRNA实现在人原代T细胞中敲除ADRB2基因

孙毓，刘丹，施明，郑骏年

《中国实验血液学杂志》

DOI

2018

Phase I dose‐escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia

O. Ottmann, C. Müller-Tidow, A. Krämer, R. Schlenk, M. Lübbert, G. Bug, U. Krug, T. Bochtler, F. Voß, T. Taube, Dan Liu, P. Garin-Chesa, H. Döhner

British Journal of Haematology

DOI

2018

Evolutionary Expression of HER2 Conferred by Chromosome Aneuploidy on Circulating Gastric Cancer Cells Contributes to Developing Targeted and Chemotherapeutic Resistance

Yi-Lin Li, Xiao-Tian Zhang, Dan Liu, J. Gong, D. Wang, Shan Li, Zhi Peng, Yan-Yan Li, Xiao-Juan Wang, P. Lin, Min Li, Lin Shen

Clinical Cancer Research

DOI

2017

Survival Benefit of Palliative Local Treatments and Efficacy of Different Pharmacotherapies in Colorectal Cancer With Lung Metastasis: Results From a Large Retrospective Study

Zheng-Hang Wang, Xi-Cheng Wang, Jia-Jia Yuan, Xiao-Tian Zhang, Jun Zhou, Ming Lu, Dan Liu, Jian Li, Lin Shen

Clinical colorectal cancer

DOI

2017

Abstract 3795: Dynamic acquisition of HER2 expression on circulating tumor cells in gastric cancer patients correlates to developing therapeutic resistance

Yi-Lin Li, Xiao-Tian Zhang, Dan Liu, J. Gong, D. Wang, Peter Lin Ping, Lin Shen

DOI

2017

Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis

Dan Liu, Jian Li, Jing Gao, Yan-Yan Li, Rui Yang, Lin Shen

BMC Cancer

DOI

2016

The patterns and timing of recurrence after curative resection for gastric cancer in China

Dan Liu, Ming Lu, Jian Li, Zuyao Yang, Qi Feng, Meng-Long Zhou, Zhen Zhang, Lin Shen

World Journal of Surgical Oncology

DOI

2015

Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity

A. Awada, H. Dumez, P. Aftimos, J. Costermans, S. Bartholomeus, K. Forceville, T. Berghmans, M. Meeus, Jessica Cescutti, G. Munzert, K. Pilz, Dan Liu, P. Schöffski

Investigational new drugs

DOI

2015

A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non-Small-Cell Lung Cancer.

P. Ellis, N. Leighl, V. Hirsh, M. Reaume, N. Blais, R. Wierzbicki, B. Sadrolhefazi, Yu Gu, Dan Liu, K. Pilz, Q. Chu

Clinical Lung Cancer

DOI

2015

A phase I study of volasertib combined with afatinib, in advanced solid tumors

J. Machiels, M. Peeters, C. Herremans, V. Surmont, P. Specenier, M. De Smet, K. Pilz, N. Strelkowa, Dan Liu, S. Rottey

Cancer Chemotherapy and Pharmacology

DOI

2013

Phase I study of volasertib (BI 6727) combined with afatinib (BIBW 2992) in advanced solid tumors.

M. Peeters, J. Machiels, K. Pilz, M. De Smet, N. Strelkowa, Dan Liu, S. Rottey

DOI

2013

A phase I dose-escalation study of volasertib (BI 6727) combined with nintedanib (BIBF 1120) in advanced solid tumors.

F. De Braud, S. Cascinu, G. Spitaleri, K. Pilz, L. Clementi, Dan Liu, P. Glomb, T. De Pas

DOI

研究方向

肿瘤免疫学与肿瘤病理生理学CAR-T细胞治疗与基因编辑

此主页由公开资料整理，尚未经学者本人认领。